Chinese medicine company PuraPharm Corporation (1498) is preparing to expand its clinic network in Hong Kong and mainland China to distribute products directly to customers, reveals its founder, chairman, chief executive, and executive director Abraham Chan Yu-ling.
He wants clinics to account for 50 percent of PuraPharm's revenue compared with 13.8 percent for the six months ended June.
Chan believes clinics will be the growth engine although the instant concentrated Chinese medicine granules contributed 69 percent revenue in the first half.
The firm is also introducing products abroad through collaborations with overseas universities and the firm it acquired.
Chan wants to grow the local clinic network, that will facilitate the B2C business, which offers a better profit margin with direct sales to customers than B2B, which constitutes mainly selling to hospitals via distributors.
PuraPharm currently operates 67 Nong's clinics in Hong Kong mainly in commercial and residential areas. It plans to open 20 clinics every year in the city.
Unlike traditional Chinese medicine clinics, Nong's are more modern and are visited by many office ladies.
"At the beginning, shopping malls did not welcome us. They thought we are like traditional Chinese medicine clinics. But now, some mall operators even invite us to open clinics."
On average, patients pay around HK$300 per visit. Each clinic is operated by a registered traditional Chinese medical practitioner, who splits the profit with PuraPharm. He says the practitioners can make a handsome income each month.
Chan adds that the firm has benefited from lower rents as a result of the retail market slowdown this year.
In China, PuraPharm runs a clinic only in Nanning, Guangxi, where three more will be available by the end of this year. And another one in Shanghai will be opened in the first quarter of 2018.
Chan says clinics in the mainland will have a few thousand square feet of space and employ practitioners in different specialities such as gynaecology and paediatrics.
"Should they prove successful, we will replicate them in other tier 1-3 cities. We aim to have 1,500 clinics in China in five years."
PuraPharm sells products through about 80 distributors in the mainland in about 300 hospitals in 20 provinces.
Chan says there are no plans to increase the coverage, but will focus on the more premium end, such as private hospitals.
Among the five concentrated Chinese medicine granule suppliers in the mainland, PuraPharm is the only non-mainland maker, with about 5 percent market share. Its production facilities are validated by the US Pharmacopeia.
Chan stresses PuraPharm cannot compete with mostly state-owned enterprises on prices, but can do so on quality.
To better control quality, supply, and costs, it has a Chinese herb field in Guizhou, where more than 50 different herbs are grown. It will expand the number of herbs species in the future.
As PuraPharm needs several hundred different types of herbs, Chan says it also buys from others.
While most people have granules for the sake of convenience, the more demanding customers want decoction pieces, made from high-quality Chinese herbs. The traditional Chinese medicine decoction pieces market is estimated to be valued at 250 billion yuan (HK$294 billion) per year.
"We use several tons of raw Chinese herbs to make granules, out of which only about 0.5 percent is good enough to make decoction pieces," Chan says.
He says that the production of decoction pieces will begin next year. He is thinking of selling via an O2O model and instructions will be given on how to prepare the decoction pieces.
PuraPharm has six clinics in Australia operated by distributors, and one self-operated clinic in Canada. It has a collaboration with University of Toronto and Western Sydney University in research and development.
However, Chan says Chinese medicines registered in Canada and Australia are not recognized in Hong Kong, which has stricter rules for clinical trials that have to be certified by both Chinese and western medical practitioners, while the former two countries are evidence-based.
For instance, a clinical trial is under way at the University of Toronto and Western Sydney University for a medicine for rheumatoid arthritis, but not in Hong Kong.
In North America, PuraPharm will leverage on K'an Herbs, which it acquired earlier this year. The US-based Chinese herbal formula maker has more than 10,000 B2B and B2C clients. The company plans to introduce some K'an Herbs products to this part of the world.
It will also introduce PuraPharm products such as flu and cough formulas to America via K'an Herbs. It also plans to open a wellness center in California.
PuraPharm has also acquired a Japanese health products company SODX last year to expand into health food.
Chan is eager to seek out more acquisition opportunities to build new businesses. He says this was one of the reasons for the listing in 2015.
"Time will tell the value of PuraPharm," says Chan, who has increased his stake to 58.09 percent of issued shares in September.